By: Derrick Padykula and Isabelle Wentzel Hallmark of Neurodegeneration Diving into the complex world of neurodegeneration unveils the long road marked by the gradual decline of neuronal cells, ultimately leading to cell death. In Parkinson’s disease (PD) and Alzheimer’s disease (AD), the accumulation of aggregated proteins and dysfunctional mitochondria is what contributes to the demise of […]
By: Derrick Padykula Ubiquitination, a ubiquitous cellular process, involves attaching ubiquitin to target proteins, influencing crucial cellular functions such as degradation, cell signaling, apoptosis, protein processing, immune response, and DNA repair. The specific ubiquitin chain type, whether M1, K6, K11, K27, K29, K33, K48, or K63-linked, dictates the downstream processing of the target protein. Delving […]
MALVERN, Pa., October 26, 2023 — LifeSensors, Inc., a leading innovator in protein degradation technologies, has been invited to speak at the 6th Annual Targeted Protein Degradation Summit 2023 in Boston, Massachusetts. The event will take place from October 30-November 2 at Westin Copley Place, Boston. LifeSensors will be exhibiting, and Dr. Karteek Kadimisetty will […]
[Malvern, PA, October 18, 2023] — LifeSensors Inc., a biotech company targeting the ubiquitin proteasome system for drug discovery and diagnostic markers, has received funding from the National Institute on Aging and National Institute of General Medicine. The funding, to the tune of $5.53 million, provides for the development of PROTAC drug discovery technologies. PROTACs […]
MALVERN, Pa., SEP 21, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glue drug discovery and neurodegeneration diagnostics has been invited to speak at the 21st annual Discovery on Target 2023. Dr. Karteek Kadimisetty, LifeSensors’ Director of Research and Development will be presenting new information, and answering questions regarding PROTACs, […]
MALVERN, PA., May 30, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTACs, molecular glues, and neurodegeneration diagnostics will disclose direct methods to detect PROTAC & molecular glue mediated ubiquitination drug targets at BIO this year in Boston, MA, June 5-8, 2023. Current methods of PROTAC & Molecular Glue discovery are time consuming, […]
By: Isabelle Wentzel Devastating Origins In the late 1950s and early 1960s, pregnant women who experienced nausea and morning sickness were prescribed thalidomide, a sedative drug meant to treat these symptoms. In early 1960, it quickly became evident that there was a link between the thousands of infants born with severe birth defects and […]
Hijacking the natural mechanism of the Ubiquitin Proteasome System (UPS) is emerging as a powerful medium in drug discovery through which Dr. Kadimisetty uses “TUBEs” as ubiquitin-binding entities to monitor PROTAC-mediated poly-ubiquitination of target proteins. The technology described wherein is a direct way to evaluate and discover PROTAC and molecular glue targets for use in […]
Discovering Unique Ubiquitin E3 Ligase Ligands to Unlock Targeted Protein degradation Gauthami Jalagadugula, Alexandra Russell1+, Kenneth Wallace1+, Janelle Pedroza and Abdul Haseeb1 * Introduction PROteolytic TArgeting Chimeras (PROTACs) have emerged as new class of drugs to target “undruggable” proteome. The human genome encodes ~ 600 E3 ligases that differentially expressed across various tissues. Only a […]
PROTACs and Molecular Glues: High-Throughput Quantitative Assays for Rationale Design Authors: Janelle Pedroza1, Kenneth Wallace1, Derrick Padykula, Alexandra Russell1, and Karteek Kadimisetty*1 Introduction PROTACs have emerged as new class of drugs that can target the “undruggable” proteome by hijacking the ubiquitin proteasome system. Traditional methods like western blotting and reporter gene assays are prone to […]
